Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease

Crohn's Disease Clinical Trial

— Welcome2  

Official title:

Open Label Long Term Clinical Trial Evaluating Efficacy and Safety of Chronic Therapy With Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor Alpha (TNF) in Patients Suffering From Crohn's Disease and Having Completed C87042 Study.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00333788
• Other study ID #: C87046
• Secondary ID: 2006-001729-24
• Status: Completed
• Phase: Phase 3
• Start date: October 2006
• Est. completion date: April 2010

Study information

• Verified date: August 2011
• Source: UCB Pharma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study will continue to assess the safety of certolizumab pegol (CDP870) as well as examine the evolution of long term efficacy in Crohn's disease patients who completed study C87042 [NCT00308581]. It will also assess the effect of subcutaneous CDP870 400 mg on direct cost parameters.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 233
• Est. completion date: April 2010
• Est. primary completion date: April 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients having completed study C87042 [NCT00308581] (previously treated with infliximab)

Exclusion Criteria:

• Subject withdraw from C87042 [NCT00308581] study

• Subject who received treatment other than certolizumab pegol and other than medications permitted in C87042 [NCT00308581] study

• Subjects from countries where certolizumab pegol is authorized in Crohn's disease treatment

• Female patients of childbearing age who are NOT practicing (in the Investigator's opinion) effective birth control. All female patients must test negative on a serum pregnancy test before study entry and negative on urine testing immediately before every certolizumab pegol administration

Related Conditions & MeSH terms

• Crohn Disease
• Crohn's Disease

Intervention

Biological:
• Certolizumab pegol (CDP870)
400 mg subcutaneous (sc) injection of Certolizumab pegol (CDP870) every 2 (Q2W) or 4 (Q4W) weeks

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
UCB Pharma

Countries where clinical trial is conducted

United States,  Austria,  Belgium,  Canada,  France,  Germany,  Italy,  Netherlands,  Spain,  Sweden,  Switzerland,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Occurrence of at Least One Study-emergent Adverse Event During the Study (Maximum 164 Weeks)	Study-emergent adverse events are defined as treatment-emergent adverse events with an onset date on or after the first study drug administration date of this study but not later than 12 weeks (84 days) after last injection.; Results are presented as the percentage of subjects with at least one treatment-emergent adverse event during this study.	Maximum 164 weeks
Secondary	Maintenance of Response at Last Visit [Up to the Maximum Study Duration Observed in the Study (Week 154) or the Withdrawal Visit for Premature Withdrawals] Among the Subjects in Clinical Response at Baseline of This Study (Week 26 of Study C87042).	Clinical response is defined as at least a 100 point decrease from Baseline of study C87042 (NCT00308581) in Crohn's Disease Activity Index (CDAI).; Subjects maintained their clinical response at Last Visit if they did not meet criteria for loss of response [CDAI score >150 points and a minimum increase in CDAI of 70 points versus Baseline of study C87042 (NCT00308581)] at 2 consecutive visits.; A CDAI score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.; Results are presented as the percentage of subjects maintaining response at Last visit.	Baseline (corresponding to Week 26 of study C87042 (NCT00308581) and Last Visit [Up to the maximum study duration observed in the study (Week 154) or the Withdrawal Visit for Premature Withdrawals]
Secondary	Clinical Response at Last Visit [Up to the Maximum Study Duration Observed in the Study (Week 154) or the Withdrawal Visit for Premature Withdrawals]	Clinical response is defined as at least a 100 point decrease from Baseline of study C87042 (NCT00308581) in Crohn's Disease Activity Index (CDAI).; CDAI is used to quantify the symptoms of Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.; Results are presented as the percentage of subjects achieving clinical response at Last visit.	Baseline of study C87042 (NCT00308581) and Last Visit [Up to the maximum study duration observed in the study (Week 154) or the Withdrawal Visit for Premature Withdrawals]
Secondary	Remission at Last Visit [Up to the Maximum Study Duration Observed in the Study (Week 154) or the Withdrawal Visit for Premature Withdrawals]	Remission is defined as a Crohn's Disease Activity Index (CDAI) score = 150 points; CDAI is used to quantify the symptoms of Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.; Results are presented as the percentage of subjects in remission at Last visit.	Last Visit [Up to the maximum study duration observed in the study (Week 154) or the Withdrawal Visit for Premature Withdrawals]
Secondary	Change From Baseline of Study C87042 (NCT00308581) in Crohn's Disease Activity Index (CDAI) at Last Visit [Up to the Maximum Study Duration Observed in the Study (Week 154) or the Withdrawal Visit for Premature Withdrawals]	CDAI is used to quantify the symptoms of Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.	Baseline of study C87042 (NCT00308581) and Last Visit [Up to the maximum study duration observed in the study (Week 154) or the Withdrawal Visit for Premature Withdrawals]
Secondary	Time to Loss of Response After Baseline of Study C87042 (NCT00308581) on Subjects Who Were in Clinical Response at Baseline of This Study	Clinical response at Baseline of this study of at least a 100 point decrease from Baseline of study C87042 in Crohn's Disease Activity Index (CDAI); Loss of response = both a CDAI score >150 points and a minimum increase in CDAI of 70 points versus Baseline (Week 26 of study C87042) as confirmed at 2 consecutive visits. Subjects losing response will be considered as having the event on the date of the first visit where response was lost. Subjects who discontinued the study without having lost response will be censored on the date of discontinuation (i.e. date of last visit performed).	Maximum 154 weeks
Secondary	Occurrence of at Least 1 Hospital Stay During the Treatment Period	The Treatment Period is defined from the first administration of study drug in C87046 to the last/withdrawal study drug administration visit.; Results are presented as the percentage of subjects with at least 1 hospital stay during the treatment period.	Maximum 152 weeks
Secondary	Occurrence of at Least 1 Hospital Stay During the Follow-Up Period	Follow-up period starts the day after the last injection up to 84 days after last injection.; Results are presented as the percentage of subjects with at least 1 hospital stay during the follow-up period.	Maximum 12 weeks
Secondary	Occurrence of at Least 1 Hospital Stay During the During the Overall Period	Overall period corresponds to both treatment and follow-up periods in C87046.; Results are presented as the percentage of subjects with at least 1 hospital stay during the overall period.	Maximum 164 weeks
Secondary	Length of Hospital Stays During the Treatment Period	The Treatment Period is defined from the first administration of study drug in C87046 to the last/withdrawal study drug administration visit.	Maximum 152 weeks
Secondary	Length of Hospital Stays During the Follow-Up Period	Follow-up period starts the day after the last injection up to 84 days after last injection.	Maximum 12 weeks
Secondary	Length of Hospital Stays During the Overall Period	Overall period corresponds to both treatment and follow-up periods in C87046.	Maximum 164 weeks
Secondary	Occurrence of at Least 1 Emergency Room Visit During the Treatment Period	The Treatment Period is defined from the first administration of study drug in C87046 to the last/withdrawal study drug administration visit.; Results are presented as the percentage of subjects with at least 1 emergency room visit during the treatment period.	Maximum 152 weeks
Secondary	Occurrence of at Least 1 Emergency Room Visit During the Follow-Up Period	Follow-up period starts the day after the last injection up to 84 days after last injection.; Results are presented as the percentage of subjects with at least 1 emergency room visit during the follow-up period.	Maximum 12 weeks
Secondary	Occurrence of at Least 1 Emergency Room Visit During the Overall Period	Overall period corresponds to both treatment and follow-up periods in C87046.; Results are presented as the percentage of subjects with at least 1 emergency room visit during the overall period.	Maximum 164 weeks
Secondary	Occurrence of at Least One Concomitant Medication Potentially Influencing Crohn's Disease During the Treatment Period	The Treatment Period is defined from the first administration of study drug in C87046 to the last/withdrawal study drug administration visit.; Medication categories are anti tumor necrosis factor (anti-TNFs), immunosuppressants, corticosteroids, 5 aminosalicylic acid (5-ASA) and antibiotics.; Results are presented as the percentage of subjects with at least 1 concomitant medication potentially influencing Crohn's disease during the treatment period.	Maximum 152 weeks
Secondary	Occurrence of at Least One Concomitant Medication Potentially Influencing Crohn's Disease During the Follow-Up Period	Follow-up period start the day after the last injection up to 84 days after last injection.; Medication categories are anti tumor necrosis factor (anti-TNFs), immunosuppressants, corticosteroids, 5 aminosalicylic acid (5-ASA) and antibiotics.; Results are presented as the percentage of subjects with at least 1 concomitant medication potentially influencing Crohn's disease during the follow-up period.	Maximum 12 weeks
Secondary	Occurrence of at Least One Concomitant Medication Potentially Influencing Crohn's Disease During the Overall Period	Overall period corresponds to both treatment and follow-up periods in C87046.; Medication categories are anti tumor necrosis factor (anti-TNFs), immunosuppressants, corticosteroids, 5 aminosalicylic acid (5-ASA) and antibiotics.; Results are presented as the percentage of subjects with at least 1 concomitant medication potentially influencing Crohn's disease during the overall period.	Maximum 164 weeks
Secondary	Occurrence of at Least 1 General Concomitant Medication During the Treatment Period	The Treatment Period is defined from the first administration of study drug in C87046 to the last/withdrawal study drug administration visit.; Results are presented as the number of subjects who used at least 1 concomitant medication during the treatment period.	Maximum 152 weeks
Secondary	Occurrence of at Least 1 General Concomitant Medication During the Follow-Up Period	Follow-up period start the day after the last injection up to 84 days after last injection.; Results are presented as the number of subjects who used at least 1 concomitant medication during the follow-up period.	Maximum 12 weeks
Secondary	Occurrence of at Least 1 General Concomitant Medication During the Overall Period	Overall period corresponds to both treatment and follow-up periods in C87046.; Results are presented as the number of subjects who used at least 1 concomitant medication during the overall period.	Maximum 164 weeks
Secondary	Occurrence of at Least 1 Concurrent Medical Procedure During the Treatment Period.	The Treatment Period is defined from the first administration of study drug in C87046 to the last/withdrawal study drug administration visit.; Results are presented as the number of subjects who had at least 1 concurrent medical procedure during the treatment period.	Maximum 152 weeks
Secondary	Occurrence of at Least 1 Concurrent Medical Procedure During the Follow-Up Period	Follow-up period start the day after the last injection up to 84 days after last injection.; Results are presented as the number of subjects who had at least 1 concurrent medical procedure during the follow-up period.	Maximum 12 weeks
Secondary	Occurrence of at Least 1 Concurrent Medical Procedure During the Overall Period	Overall period corresponds to both treatment and follow-up periods in C87046.; Results are presented as the number of subjects who had at least 1 concurrent medical procedure during the overall period.	Maximum 164 weeks

External Links

•   FDA Safety Alerts and Recalls
•   Product Information